Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $46.38

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among […]

Leave a Reply

Your email address will not be published.

Previous post Host Hotels & Resorts (NASDAQ:HST) Downgraded by JPMorgan Chase & Co.
Next post Analysts Set AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target at $15.83